Clinical Research Awards for Neurofibromatosis: Request for Letters of Intent
The Children’s Tumor Foundation announces a call for Letters of Intent for Clinical Research Awards of up to $100,000. Clinical Research Awards seeks broad-thinking novel ideas to conduct pilot clinical trials of candidate therapeutics for the treatment of tumors and other manifestations of NF1, NF2 and schwannomatosis; OR innovative studies ancillary or adjunct to clinical trials that - if successful - will contribute to the advancement of effective clinical therapies for neurofibromatosis.
Examples of projects encouraged may include but are not limited to:
- Biomarker studies adjunct to an ongoing clinical trial (may be e.g. molecular, imaging or genetic biomarkers, or other novel outcome parameters) that may better inform on and ultimately help accelerate a clinical trial.
- Preclinical/clinical collaborative studies (‘clinical co-trials’). Note however that all studies must include a clinical element – preclinical-only studies are not eligible.
- Applications to fund pilot neurofibromatosis clinical trials are welcomed an encouraged.
It is anticipated that CTF will fund up to four Clinical Research Awards of up to $100,000 (including overheads/indirect costs).
Application Process and Timeline
LOI’s due: September 15, 2010
Applicants notified: October 4, 2010
Successful LOIs will be invited to submit a full application.
Full applications due: November 15, 2010
Applicants notified: Mid-December 2010
Funding commences as early as: January 2011
Before submitting your LOI, you are strongly encouraged to contact me to discuss your idea.
Kim Hunter-Schaedle, Ph.D.
Chief Scientific Officer
Children's Tumor Foundation
Khunter-schaedle@ctf.org
Tel: 212-344-6633 x231
